Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.

doi:10.1002/(sici)1097-0347(199808)20:5<385::aid-hed5>3.0.co;2-u

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.

Head & neck - 1 Aug 1998

Langer C J, Schaebler D, Sauter E, DeMaria D, Johnson C, Reilly D M, Clark J, Leighton J, Aks C, Litwin S, Ridge J A

Abstract excerpt

BACKGROUND: 5-Fluorouracil (5-FU), as a single agent, produces a 15% response rate in advanced squamous cell carcinoma of the head and neck (SCCHN). N-phosphonacetyl-L-aspartate (PALA) inhibits pyrimidine biosynthesis and increases incorporation of 5-FU metabolites into ribonucleic acid (RNA). Re...

Topics

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Aspartic Acid
Carcinoma, Squamous Cell
Drug Administration Schedule
Female
Fluorouracil
Genes, p53
Head and Neck Neoplasms
Humans
Interferon-alpha
Male
Middle Aged

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Mutation

Neoplasm Recurrence, Local

Phosphonoacetic Acid

Survival Analysis

Source

Open in PubMed

Identifiers

PMID: 9663665
DOI: 10.1002/(sici)1097-0347(199808)20:5<385::aid-hed5>3.0.co;2-u

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-9663665-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.